Is This Stock a Screaming Buy: Agile Therapeutics, Inc. (NASDAQ:AGRX)

Equity Research firms currently have a positive stance on shares of Agile Therapeutics, Inc. (NASDAQ:AGRX). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.50. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $16.17 on a short term basis.

At the time of writing, the stock was trading at $7.35. This represents a change from the opening price of 0.87%. In terms of performance, year to date, the stock is -26.23%. The monthly stock performance comes in at 0.56%. For the quarter, shares are performing at -3.74%. Weekly performance analysis shows the equity at 3.45%.

In taking a look at technical levels, shares are trading 2.60% away from the 50 day simple moving average and 6.66% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -29.39% away from it’s 52- week high and 38.16% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Agile Therapeutics, Inc.’s RSI stands at 54.49. In looking at volatility levels, the shares saw weekly volatility of 4.89% and 4.79% over the past month.

Leave a Comment